Neuropathy: Diagnosis & Management

  - 周邊神經教學

- Topics
  - Etiology approach
  - Common neuropathies:
    - Diabetic neuropathy vs. Neuropathy in diabetes
  - Diagnosis of painful neuropathy
    - Skin biopsy and neuroimaging
  - Treatment:
    - Inflammatory neuropathies
    - Neuropathic pain
Overview of Neuropathy

• Typical presentations of neuropathy
  • Neurological deficits (motor, sensory, autonomic) in the territory of peripheral nerves
    • Motor: lower neuron type (vs. myopathy, myelopathy)

• Patterns of neuropathy and etiology
  • Mononeuropathy: mechanical
  • Radiculopathy: mechanical
  • Polyneuropathy (length-dependent, symmetric absence of ankle jerk): metabolic, toxic, autoimmune
  • Mononeuropathy multiplex: vascular (ischemic, inflammation), autoimmune
Diabetic sensory neuropathy: Clinical presentations

- 45 y/o male with diabetes for 2 years under control with oral hypoglycemic agents; HbA1c=8.0%
- Tingling, prickling, burning over feet for 4 months
- Paresthesia over fingers for 1 months
- Sensory neuropathy
  - Large-fiber neuropathy
  - Small-fiber neuropathy
Neuropathy in diabetes?

- 75 y/o female with diabetes for 6 years under regular medications of oral hypoglycemic agents; HbA1c = 7.2%
- Mild paresthesia over both feet for 2 years
- Subacute onset of pain and weakness involving the right thigh muscles with progression over 2 months
NE: Neuropathy in diabetes?

• Motor system
  • Muscle strength (R/L):
    • Hip flexor: 3+/5
    • Knee extensor: 3+/5; Knee flexor: 4/5
    • Plantar dorsiflexor: 4/5; Plantar flexor 4/5
  • Deep tendon reflex (R/L):
    • Knee jerk: -/+  
    • Ankle jerk: +/-  

• Sensory system
  • Vibration: reduced in bilateral lateral malleoli
  • Pin-prick: reduced over bilateral foot dorsum
  • Sphincters for urine and stool: intact
Laboratory examinations: Neuropathy in diabetes

- Electrophysiology
  - Nerve conduction studies: reduced amplitude of motor and sural nerves, suggesting sensory and motor neuropathy
  - Electromyography: active denervation over rectus femoris muscles with polyphasic waves of 10-15 ms in duration and 1-2 mV in amplitude

- Neuroimaging
  - MRI of the lumbar sacral spine: lumbar stenosis s/p laminectomy L3-L5 with foraminaotomy

Diagnosis?
Pathology of lumbosacral plexoradiculopathy: microvasculitis

Dyck PJ, Neurol 53:2113, 1999

- Focal fiber loss
- Perivascular mononuclear infiltration
- Destruction of vascular wall
Spectrum of Diabetic Neuropathies

- **Mononeuropathy**
  - Carpal tunnel syndrome

- **Symmetric/Systemic polyneuropathy**
  - Sensory-predominant polyneuropathy
  - Autonomic neuropathy

- **Asymmetric neuropathy**
  - Mononeuropathy multiplex
  - Lumbosacral plexoradiculopathy ("DM amyotrophy")
Charcot-Marie-Tooth

Jean-Martin Charcot      Pierre Marie      Howard Henry Tooth
Charcot-Marie-Tooth (CMT)

- The most common form of hereditary neuropathies
- Hereditary motor and sensory neuropathy (HMSN)

- Presentations
  - “Peroneal muscular atrophy”, “inverted bottle”
  - pes cavus, high-arched foot

- Pathology and electrophysiologic phenotypes
  - type 1 (demyelination)
  - type 2 (axonal degeneration)

- **Genotype**: CMT1A (peripheral myelin protein 22, PMP22); CMT1B (myelin protein zero, MPZ, P0); CMTX (connexin 32) et al
Charcot-Marie-Tooth: Clinical presentations
Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser

N.-C. Yang, MS*  
M.-J. Lee, MD, PhD*  
C.-C. Chao, MD*  
Y.-T. Chuang, MS  
W.-M. Lin, MS  
M.-F. Chang, MS  
P.-C. Hsieh, BS  
H.-W. Kan, BS  
Y.-H. Lin, BS  
C.-C. Yang, MD  
M.-J. Chiu, MD, PhD  
H.-H. Liou, MD, PhD  
S.-T. Hsieh, MD, PhD

ABSTRACT

Objective: Familial amyloid polyneuropathy (FAP) due to amyloidogenic transthyretin (TTR) is often associated with impairment of thermociceptive functions. This study investigated skin innervation and its clinical significance in genetically defined FAP due to a hot-spot Ala97Ser TTR mutation (Ala97Ser).

Methods: Skin biopsies were performed on the distal leg of patients with Ala97Ser, and intraepidermal nerve fiber (IENF) densities were quantified.

Results: There were 19 unrelated patients with Ala97Ser manifesting a late-onset (59.47±5.70 years) generalized neuropathy with disabling motor, sensory, and autonomic symptoms. Against a background of a slowly progressive course, 7 patients (36.8%) exhibited additional rapid declines in neurologic deficits, which were associated with elevation of the protein content in the CSF (p < 0.001). The IENF density was markedly reduced in Ala97Ser patients compared to age- and gender-matched controls (0.99±1.11 vs 8.31±2.87 fibers/mm, p < 0.001). Skin denervation was present in all patients and was lower in patients with a higher disability grade (0.17±0.26 vs 1.37±1.16 fibers/mm, p = 0.003). Albuminocytologic dissociation in the CSF was observed in 14 patients (73.7%), and the IENF density was negatively correlated with the CSF protein concentration (p = 0.015).

Conclusions: Skin denervation was common in Ala97Ser, and degeneration of cutaneous nerve terminals was correlated with the severity of clinical phenotypes and the level of CSF protein.  
Neurology® 2010;75:532-538
Familial amyloid polyneuropathy with mutated transthyretin (TTR Ala97Ser)

- Mutation of G to T to cause transthyretin (Ala97Ser): unique in Taiwan
- Val30Met: the most common in Portugal, Sweden, and Japan
Familial amyloid polyneuropathy with mutated transthyretin (Ala97Ser) in Taiwan

- The most common genetic neuropathy of adult-onset with pan-modality involvement and axonal degeneration in Taiwan
- Marked neuropathic pain as a major symptom
- Progressive weakness of muscle strength
- Dysautonomia, especially diarrhea, frequently as one of initial symptoms
- Some exhibited rapid decline on a background of slowly progressive course

(Yang et al, Neurol, 2010)
Guillain-Barré syndrome (GBS)

Ascending paralysis in 1859
Jean Baptiste Octave Landry de Thézillat

Reduced reflexes, Increased CSF protein
Without pleocytosis, in 1916

Georges Charles Guillain
Jean-Alexandre Barré
André Strohl
Guillain-Barré syndrome (GBS)

Progressive weakness

Day 1
Lower limbs

Day 3
Upper limbs

Day 7
Respiratory failure
Inflammatory neuropathies: GBS and CIDP

- Guillain-Barré syndrome (GBS)
  - 20-30% associated previous infections, *Campylobacter jejuni* et al; usually < 4 weeks to reach peak and monophasic
  - molecular mimicry: autoantigen (gangliosides et al)
  - variants of (limb/bulb weakness and respiratory failure):
    - acute inflammatory demyelinating polyneuropathy (AIDP)
    - acute motor axonal neuropathy (AMAN)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
  - course: > 2 months
  - with underlying immune dysregulations
Therapy for inflammatory neuropathies

- **Treatment strategies**
  - Plasma exchange (PE) / Plasmapheresis
  - Intravenous immunoglobulin (IVIg)
  - Corticosteroid therapy
    - Pulse methylprednisolone therapy
    - Oral prednisolone therapy
  - Azathioprine (Imuran)
  - Cyclophosphamide (Endoxan)

- **Principles**
  - GBS: only PE or IVIG
  - CIDP: PE or IVIG followed by maintenance immunotherapy
Peripheral process (Peripheral nerve)

Muscle
Tendon
Joint

Sensory neuron

Skin
Skin biopsy (3 mm-punch)

Two weeks later  One year later
Sensory neuropathy (small-fiber type)  Normal subject

intra-epidermal nerve fiber (IENF)

**IENF density**: objective and quantifiable parameter of skin innervation  
(European Federation of Neurological Societies Skin Biopsy Task Force, 2010)
Small-fiber neuropathy in Diabetes

Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments

Chia-Tung Shun, Yang-Chyuan Chang, Huey-Peir Wu, Song-Chou Hsieh, Whei-Min Lin, Yea-Hui Lin, Tong-Yuan Tai and Sung-Tsang Hsieh

Departments of Pathology, Neurology and Internal Medicine, National Taiwan University Hospital and Departments of Forensic Medicine and Anatomy and Cell Biology, National Taiwan University College of Medicine, Taipei, Taiwan

Correspondence to: Dr Sung-Tsang Hsieh, Department of Anatomy and Cell Biology, National Taiwan University College of Medicine, 1 Jen-Ai Road, Sec. 1, Taipei 10018, Taiwan
E-mail: sthsieh@ntumc.org
Skin innervation (IENF density) in DM

(Shun CT, Brain 127:1593-1605, 2004)
Relationship between skin innervation (IENF density) and pain

Table 7 Relationship between intraepidermal nerve fibre density and amplitude of sural sensory action potential with clinical parameters

<table>
<thead>
<tr>
<th></th>
<th>IENF density (fibres/mm)</th>
<th>Sural SAP amplitude (µV)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median (range)</td>
<td>P</td>
</tr>
<tr>
<td>Painful neuropathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (9)*</td>
<td>0.17 (0–4.23)</td>
<td>0.1137</td>
</tr>
<tr>
<td>No (29)</td>
<td>1.44 (0–6.80)</td>
<td></td>
</tr>
<tr>
<td>Symptomatic site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (7)</td>
<td>0 (0–1.68)</td>
<td>0.0116*</td>
</tr>
<tr>
<td>No (31)</td>
<td>1.25 (0–6.8)</td>
<td></td>
</tr>
</tbody>
</table>

*Statistically significant.

(Shun CT, Brain 127:1593-1605, 2004)
Brain activations in pain due to diabetic neuropathy

Tseng et al, Human Brain Mapping, 2013
Pain-activating system

- Lateral pain system
  - Discriminatory component
- Medial pain system
  - Affective component

(Schweinhardt and Bushnell, 2010)
今年47歲的林小姐，4年前確診第3期乳癌，手術後因淋巴有多處癌細胞蔓延，開始化療，她直喊，治療的痛苦前所未有，打完針劑後，晚上回家開始感覺到手腳末梢神經有刺痛感，像是有人拿著針不斷的戳我的指縫，彷彿滿清十大酷刑。

乳癌病友協會今年8月針對307位病友進行這項「乳癌病友疼痛問題」調查，結果發現，在治療期有高達8成8、不分癌症期別的病友經歷疼痛，其中超過6成是中度以上疼痛，但在全部重度疼痛的病友中，僅有3成8有接受疼痛治療。

有時候疼痛比死亡更可怕！中華民國乳癌病友協會林嚴鳳秘書長表示，調查也顯示，選擇忍痛的病友，比率達42%，遠多於尋求醫師協助的40%，顯示目前抗癌的疼痛控制還有很大進步的空間，且癌症疼痛不只發生在末期癌症患者身上。

調查指出，雖然半數以上病友都曾有疼痛問題，但僅有4成4從未接受過疼痛評估，且7成2的病友沒有使用止痛藥物，另還有超過3成使用止痛藥之後，仍有中度以上的疼痛，不是沒有藥，就是使用的藥物未能達到解除疼痛的效果。

http://www.nownews.com/n/2014/12/03/1530890
Descending inhibitory system

• Pain-inhibition
  • Periaqueductal gray matter (PAG)

• Monoaminergic
  • Serotonin (5-HT)
  • Norepinephrine (NE)

(Schweinhardt and Bushnell, 2010)
Specific Treatment of Neuropathic Pain

- **Anti-depressants**
  - Imipramine (Tofranil)
  - Despramine / Amitriptyline
  - Duloxetin (Cymbalta)
  - Venlafaxine (Efexor)

- **Anticonvulsants**
  - Clonazepam (Rivotril)
  - Pregabalin (Lyrica)
  - Oxcarbazepine (Trileptal)
  - Phenytoin (Aleviatin)
  - Gabapentin (Neurontin)

- **Opioid**
  - Tramadol, Ultracet

- **Local patch**
  - Cpsaicin
  - Lidocaine